Non-invasive assessment of liver fibrosis progression in hepatitis C patients retreated for 96 weeks with antiviral therapy: A randomized study

Liver International

Volumn 30, Issue 7, 2010, Pages 1049-1058

  Zarski, Jean Pierre ^a,b   Sturm, Nathalie ^a,b   Desmorat, Hervé ^c   Melin, Pascal ^d   Raabe, Jean Jacques ^e   Bonny, Corinne ^f   Sogni, Philippe ^g   Pinta, Alexandrina ^h   Rouanet, Stéphanie ^h   Babany, Gérard ^h   Cheveau, Alice ^a   Chevallier, Michèle ⁱ  

^a GRENOBLE UNIVERSITY HOSPITAL   (France)

^b INSTITUT ALBERT BONNIOT   (France)

^c Clinique du Parc   (France)

^d Department of Internal Medicine   (France)

^e Bon Secours Hospital   (France)

^f HÔTEL DIEU   (France)

^g Hôpital Cochin ^*  (France)

^h Roche   (France)

ⁱ Institut Merieux   (France)

Author keywords

Blood tests of fibrosis; Chronic hepatitis C; Liver fibrosis; Morphometry

Indexed keywords

ALPHA TOCOPHEROL; ANTIVIRUS AGENT; BIOLOGICAL MARKER; INTERFERON; PEGINTERFERON; PEGINTERFERON ALPHA2A; RIBAVIRIN; ALPHA INTERFERON; ALPHA2A INTERFERON; MACROGOL DERIVATIVE; RECOMBINANT PROTEIN; VIRUS RNA;

ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HISTOPATHOLOGY; HUMAN; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER FIBROSIS; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MORPHOMETRICS; MULTICENTER STUDY; NEUTROPENIA; NON INVASIVE PROCEDURE; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; BIOPSY; BLOOD; COMPARATIVE STUDY; COMPLICATION; DRUG EFFECTS; FRANCE; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; LIVER; LIVER CIRRHOSIS; MIDDLE AGED; PATHOLOGY; PREDICTIVE VALUE; TIME;

ADULT; ALPHA-TOCOPHEROL; ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; BIOPSY; DISEASE PROGRESSION; FEMALE; FRANCE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; LIVER; LIVER CIRRHOSIS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; PREDICTIVE VALUE OF TESTS; RNA, VIRAL; TIME FACTORS; TREATMENT OUTCOME; INTERFERON-ALPHA; RECOMBINANT PROTEINS;

EID: 77957139181     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2010.02265.x     Document Type: Article

References (43)

1. Tong MJ, El Farr NS, Reikes AR. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995, 332:1463-66.
2. Seeff LB. Natural history of chronic hepatitis C. Hepatology 2002, 36:S35-46.
3. Fried MW, Shiffman ML, Reddy KR. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002, 347:975-82.
4. Manns MP, McHutchinson JG, Gordon S. Peg-Interferon alfa-2b plus ribavirin compared with interferon alfa 2-b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001, 358:958-65.
5. Poynard T, McHutchison J, Davis GL. Impact of interferon alfa-2b and ribavirin on the progression of liver fibrosis in patients with chronic hepatitis C. Hepatology 2000, 32:1131-7.
6. Poynard T, Ratziu V, Benhamou Y. Fibrosis in patients with chronic hepatitis C: detection and significance. Semin Liver Dis 2000, 20:47-55.
7. Nishiguchi S, Shiomi S, Nakatani S. Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis. Lancet 2001, 357:196-7.
8. Papatheodoridis GV, Papadimitropoulos VC, Hadziyannis SJ. Effect of interferon therapy on the development of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: a meta-analysis. Aliment Pharmacol Ther 2001, 15:689-98.
9. Shiffman ML, Hofmann CM, Thompson EB. Relationship between biochemical, virological and histological response during interferon treatment of chronic hepatitis C. Hepatology 1997, 26:780-5.
10. Sokol RJ, Deveraux M, Mierau GW, Hambidge KM, Shikes RH. Oxidant injury to hepatic mitochondrial lipids in rats with dietary copper overload. Gastroenterology 1990, 99:1061-71.
11. Kelleher T, Afdhal N. Maintenance therapy for chronic hepatitis C. Current Gastroenterol Rep 2005, 7:50-3.
12. Di Bisceglie AM, Shiffman ML, Everson GT. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med 2008, 359:2429-41.
13. Li D, Friedman SL. Liver fibrogenesis and the role of hepatic stellate cells: new insights and prospects for therapy. J Gastroenterol Hepatol 1999, 14:618-33.
14. Kawada N, Seki S, Inoue M, Kuroki T. Effect of antioxidants, resveratrol, quercetin, and N-acetylcysteine, on the functions of cultured rat hepatic stellate cells and Kuppfer cells. Hepatology 1998, 27:1265-74.
15. Houglum K, Venkataramani A, Lyche K, Chojkier M. A pilot study of the effects of alfa-tocopherol on hepatic stellate cell activation in chronic hepatitis C. Gastroenterology 1997, 113:1069-73.
16. Goodman Z, Becker RL, Pockros PJ, Afdhal NH. Progression of fibrosis in advanced chronic hepatitis C: evaluation by morphometric image analysis. Hepatology 2007, 45:886-94.
17. Kage M, Shimamatu K, Nakashima E, Kojiro M, Inoue O, Yano M. Long-term evolution of fibrosis from chronic hepatitis to cirrhosis in patients with hepatitic C: morphometric analysis of repeated biopsies. Hepatology 1997, 25:1028-31.
18. Lazzarini AL, Levine RA, Ploutz-Snyder RJ, Sanderson SO. Advances in digital quantification technique enhance discrimination between mild and advanced liver fibrosis in chronic hepatitis C. Liver Int 2005, 25:1142-9.
19. O'Brien MJ, Keating NM, Elderiny S. An assessment of digital image analysis to measure fibrosis in liver biopsy specimens of patients with chronic hepatitis C. Am J Clin Pathol 2000, 114:712-8.
20. Pilette C, Rousselet MC, Bedossa P. Histological evaluation of liver fibrosis: quantitative image analysis vs semi-quantitative scores. Comparison with serum markers. J Hepatol 1998, 28:439-46.
21. Caballero T, Perez-Milena A, Masseroli M. Liver fibrosis assessment with semiquantitative indexes and image analysis quantification in sustained-responder and non-responder interferon-treated patients with chronic hepatitis. C. J Hepatol 2001, 34:740-747.
22. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR cooperative study group. Hepatology 1994, 20:15-20.
23. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR cooperative study group. Hepatology 1996, 24:289-93.
24. Ishak K, Baptista A, Bianchi L. Histological grading and staging of chronic hepatitis. J Hepatol 1995, 22:696-9.
25. Poynard T, Morra R, Halfon P. Meta-analyses of FibroTest diagnostic value in chronic liver disease. BMC Gastroenterol 2007, 7:40.
26. Goodman ZD, Stoddard AM, Bonkovsky HI. Fibrosis progression in chronic hepatitis C: morphometric image analysis in the HALT-C trial. Hepatology 2009, 50:1738-49.
27. Shiffman ML, Morishima C. Effect of HCV RNA suppression during Peginterferon alfa-2a maintenance therapy on clinical outcomes in the HALT-C Trial. Gastroenterology 2009, 137:1986-94. HALT-C Trial Group.
28. Brown KE, Poulos JE, Li L. Effect of vitamin E supplementation on hepatic fibrogenesis in chronic dietary iron overload. Am J Physiol 1997, 272:G116-123.
29. Von Herbay A, Stahl W, Niederau C, Sies H. Vitamin E improves the aminotransferase status of patients suffering from viral hepatitis C: a randomized, double-blind, placebo-controlled study. Free Rad Res 1997, 27:599-605.
30. Fontaine H, Fernandes S, Squalli N. The one-year antifibrotic pentoxyphillin/alpha-tocopherol association does not limit liver firosis progression in patients with chronic hepatitis C - ANRS HC 10. Hepatology 2009, 50:1029A.
31. Heathcote EJ, Shiffman ML, Cooksley GE. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000, 343:1673-80.
32. Reddy KR, Wright TL, Pockros PJ. Efficacy and safety of pegylated (40-kd) interferon α-2a compared with interferon α-2a in in non cirrhotic patients with chronic hepatitis C. Hepatology 2001, 33:433-8.
33. Guerret S, Desmoulière A, Chossegros P. Long-term administration of interferon-α in non responder patients with chronic hepatitis C: follow-up of liver fibrosis over 5 years. J Viral Hepat 1999, 6:125-33.
34. Manabe N, Chevallier M, Chossegros P. Interferon-alpha 2b therapy reduces liver fibrosis in chronic non-A, non-B hepatitis; a quantitative histological evaluation. Hepatology 1993, 18:1344-9.
35. Bedossa P, Dargère D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003, 38:1449-57.
36. Rousselet MC, Michalak S, Dupré F. Sources of variability in histological scoring of chronic viral hepatitis. Hepatology 2005, 41:257-64. Hepatitis Network 49
37. Bedossa P. Assessment of hepatitis C: non-invasive fibrosis markers and/or liver biopsy. Liver Int 2009, 29((Suppl. 1)):19-22.
38. Patel K, Benhamou Y, Yoshida EM. An independent and prospective comparison of two commercial fibrosis marker panels (HCV FibroSURE and FIBROSpect II) during albinterferon alfa-2b combination therapy for chronic hepatitis C. J Viral Hepat 2009, 16:178-86.
39. Poynard T, Imbert-Bismut F, Ratziu V. Biochemical markers of liver fibrosis in patients infected by hepatitis C virus: longitudinal validation in a randomized trial. J Viral Hepat 2002, 9:128-33.
40. Calès P, de Ledinghen V, Halfon P. Evaluating the accuracy and increasing the reliable diagnosis rate of blood tests for liver fibrosis in chronic hepatitis C. Liver Int 2008, 28:1328-31.
41. Castéra L, Denis J, Babany G, Roudot-Thoraval F. Evolving pratices of non-invasive markers of liver fibrosis in patients with chronic hepatitis C in France: time for new guidelines? J Hepatol 2007, 46:529-30.
42. Roudot-Thoraval F, Ouzan D, Denis J. Liver fibrosis assessment in chronic hepatitis C: evolution of clinical practice in a large cohort of 4546 patients between 2003 and 2006. J Hepatol 2008, 48((Suppl. 2)):S312. (abstract)
43. Afdhal NH, Levine R, Brown R. Colchicine versus Peg-Interferon alfa-2b long term therapy: results of the 4 year COPILOT trial. J Hepatol 2008, 48:S4.